These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12019099)

  • 1. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin.
    Singh KV; Weinstock GM; Murray BE
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1845-50. PubMed ID: 12019099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin.
    Singh KV; Murray BE
    Antimicrob Agents Chemother; 2005 Jan; 49(1):32-9. PubMed ID: 15616272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
    Duh RW; Singh KV; Malathum K; Murray BE
    Microb Drug Resist; 2001; 7(1):39-46. PubMed ID: 11310802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility and molecular analysis of Enterococcus faecalis originating from endodontic infections in Finland and Lithuania.
    Reynaud Af Geijersstam AH; Ellington MJ; Warner M; Woodford N; Haapasalo M
    Oral Microbiol Immunol; 2006 Jun; 21(3):164-8. PubMed ID: 16626373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
    Bozdogan B; Leclercq R
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
    Eliopoulos GM; Wennersten CB
    Antimicrob Agents Chemother; 2002 May; 46(5):1319-24. PubMed ID: 11959562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Enterococcus faecium with macrolide resistance and reduced susceptibility to quinupristin/dalfopristin in a Japanese hospital: detection of extensive diversity in erm(B)-regulator regions.
    Isogai N; Urushibara N; Kawaguchiya M; Ghosh S; Suzaki K; Watanabe N; Quiñones D; Kobayashi N
    Microb Drug Resist; 2013 Aug; 19(4):298-307. PubMed ID: 23442208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
    Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
    Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility and macrolide resistance genes in Enterococcus faecium with reduced susceptibility to quinupristin-dalfopristin: level of quinupristin-dalfopristin resistance is not dependent on erm(B) attenuator region sequence.
    López F; Culebras E; Betriú C; Rodríguez-Avial I; Gómez M; Picazo JJ
    Diagn Microbiol Infect Dis; 2010 Jan; 66(1):73-7. PubMed ID: 18653303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of telithromycin and quinupristin/dalfopristin against methicillin-resistant coagulase-negative staphylococci with defined resistance genotypes.
    Novotná G; Spízek J; Janata J
    Folia Microbiol (Praha); 2007; 52(6):593-9. PubMed ID: 18450221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.
    Fantin B; Leclercq R; Garry L; Carbon C
    Antimicrob Agents Chemother; 1997 May; 41(5):931-5. PubMed ID: 9145847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999.
    Johnson AP; Warner M; Hallas G; Livermore DM
    J Antimicrob Chemother; 2000 Jul; 46(1):125-8. PubMed ID: 10882701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis.
    Coque TM; Singh KV; Weinstock GM; Murray BE
    Antimicrob Agents Chemother; 1999 Jan; 43(1):141-7. PubMed ID: 9869579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China.
    Wang S; Guo Y; Lv J; Qi X; Li D; Chen Z; Zhang X; Wang L; Yu F
    BMC Microbiol; 2016 Oct; 16(1):246. PubMed ID: 27769188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.